Interius BioTherapeutics Receives HREC Approval and CTN Clearance from the TGA to Commence a Phase 1 Clinical Trial for Its First-in-Class In Vivo CAR Therapeutic for B Cell Malignancies July 9, 2024
Interius BioTherapeutics to Present In Vivo CAR Data in Oncology and Autoimmunity Programs at the American Society of Gene and Cell Therapy 27th Annual Meeting April 24, 2024
Interius BioTherapeutics Highlights Strong Preclinical Data Supporting In Vivo Chimeric Antigen Receptor (CAR) Vector Evaluation in Clinic June 21, 2023
Interius BioTherapeutics Announces Successful Manufacturing Partnership with WuXi Advanced Therapies May 9, 2023
Interius BioTherapeutics Announces Granting of US Patent to Support in Vivo Cell-Specific Gene Delivery Platform December 22, 2021
